News

Greens Hx product offers high density nutrition with plant extracts from 39 super foods including sea greens, soy lecithin, vegetables, herbs, spices, royal jelly, apple pectin, plant enzymes

Following the transaction, Xellia will revert to Danish ownership with headquarters in Denmark. Xellia develops and manufactures anti-infective therapies for multi-drug resistant infections and supplies Vancomycin and Colistimethate

Global Pharmaceuticals, the generics division of Impax, commenced product shipment, as part of a distribution, license, development and supply agreement with AstraZeneca UK. Zomig is indicated to treat

The trial will test the safety and efficacy of intra-articular injections of autologous human adipose-derived mesenchymal progenitor cells (haMPC) to reduce inflammation and regenerate damaged joint tissues. Cellular

IL-13 is an immune regulatory cytokine and IL-13Ra2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. ICT-107 is the

The partnership will leverage DBV’s skin patch, Viaskin, and Stallergenes’ expertise in respiratory allergies in developing immunotherapy treatments for respiratory allergies. DBV Technologies chairman and CEO Dr. Pierre-Henri

The two-stage trial is performed as a double masking test at each stage. It will include around 120 study subjects in the first and second stage studies. R-Tech

The novel anti-IL-6 monoclonal antibody RYI-008 is believed to have a potential to define new paradigm in the treatment of autoimmune diseases and cancer. RuiYi president and CEO

Paradigm 2 is a multi-centre, blinded study designed to assess the safety and efficacy of the glycopegylated recombinant factor IX as on-demand or prophylactic treatment against haemophilia B.